Glaukos Price to Book Ratio 2014-2022 | GKOS

Historical price to book ratio values for Glaukos (GKOS) over the last 10 years. The current price to book ratio for Glaukos as of January 27, 2023 is 4.16.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Glaukos Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-01-27 48.04 4.17
2022-09-30 53.24 $11.51 4.63
2022-06-30 45.42 $11.86 3.83
2022-03-31 57.82 $12.69 4.56
2021-12-31 44.44 $12.50 3.55
2021-09-30 48.17 $12.83 3.76
2021-06-30 84.83 $12.57 6.75
2021-03-31 83.93 $12.82 6.54
2020-12-31 75.26 $14.75 5.10
2020-09-30 49.52 $14.76 3.36
2020-06-30 38.42 $14.87 2.58
2020-03-31 30.86 $14.54 2.12
2019-12-31 54.47 $15.48 3.52
2019-09-30 62.51 $5.15 12.14
2019-06-30 75.40 $5.13 14.71
2019-03-31 78.37 $5.11 15.35
2018-12-31 56.17 $4.82 11.67
2018-09-30 64.90 $4.54 14.29
2018-06-30 40.64 $4.23 9.61
2018-03-31 30.83 $4.11 7.51
2017-12-31 25.65 $3.99 6.43
2017-09-30 33.00 $3.82 8.63
2017-06-30 41.47 $3.66 11.34
2017-03-31 51.30 $3.59 14.30
2016-12-31 34.30 $3.46 9.93
2016-09-30 37.74 $3.31 11.41
2016-06-30 29.16 $3.19 9.13
2016-03-31 16.86 $3.03 5.57
2015-12-31 24.69 $2.96 8.35
2015-09-30 24.19 $2.95 8.19
2015-06-30 28.98 $2.97 9.77
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $2.298B $0.294B
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $226.442B 23.68
Edwards Lifesciences (EW) United States $48.354B 33.28
Alcon (ALC) Switzerland $36.722B 31.62
STERIS (STE) Ireland $20.456B 25.46
Teleflex (TFX) United States $11.305B 18.34
Fresenius Medical Care AG KGaA (FMS) Germany $10.584B 10.62
Penumbra (PEN) United States $9.289B 2223.46
Globus Medical (GMED) United States $7.506B 38.16
Integer Holdings (ITGR) United States $2.380B 19.11
AVANOS MEDICAL, INC (AVNS) United States $1.402B 19.97
Paragon 28 (FNA) United States $1.303B 0.00
Nevro (NVRO) United States $1.291B 0.00
Artivion (AORT) United States $0.505B 0.00